Research programme: monocyte therapeutics - Therapeutic Solutions International
Latest Information Update: 30 Mar 2021
At a glance
- Originator Therapeutic Solutions International
- Class Anti-inflammatories; Behavioural disorder therapies; Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurogenic inflammation; Suicidal ideation
Most Recent Events
- 11 Mar 2021 Therapeutic Solutions International files for patent protection for covering the use of manipulated cord blood derived monocytes for prevention of suicidal ideations as well as inflammation of the brain
- 11 Mar 2021 Therapeutic Solutions International plans a clinical trial for Suicidal ideations and Neurogenic inflammation
- 04 Mar 2021 Therapeutic Solutions International has patents pending for, "Therapeutic Monocytes for Prevention of Suicidal Ideation" (March 2021, Therapeutic Solutions International website)